Hologic Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 984 shares of the stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $38.57, for a total value of $37,952.88. Following the completion of the transaction, the vice president now directly owns 9,065 shares in the company, valued at approximately $349,637.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Karleen Marie Oberton also recently made the following trade(s):

  • On Monday, November 7th, Karleen Marie Oberton sold 522 shares of Hologic stock. The shares were sold at an average price of $38.53, for a total value of $20,112.66.
  • On Monday, October 10th, Karleen Marie Oberton sold 31,470 shares of Hologic stock. The shares were sold at an average price of $40.00, for a total value of $1,258,800.00.

Hologic Inc. (NASDAQ:HOLX) opened at 36.74 on Monday. The firm has a 50-day moving average price of $38.05 and a 200-day moving average price of $36.58. The company has a market capitalization of $10.20 billion, a P/E ratio of 31.67 and a beta of 1.13. Hologic Inc. has a 1-year low of $31.84 and a 1-year high of $41.66.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.50 by $0.02. Hologic had a return on equity of 26.76% and a net margin of 11.68%. The company had revenue of $726.80 million for the quarter, compared to analyst estimates of $721.52 million. During the same quarter in the prior year, the company earned $0.43 EPS. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. On average, analysts forecast that Hologic Inc. will post $2.15 EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Several large investors have recently made changes to their positions in HOLX. Panagora Asset Management Inc. increased its position in Hologic by 247.3% in the first quarter. Panagora Asset Management Inc. now owns 1,682,853 shares of the company’s stock worth $58,058,000 after buying an additional 1,198,338 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in Hologic during the first quarter worth $689,000. Bellevue Group AG purchased a new position in Hologic during the first quarter worth $2,795,000. Envestnet Asset Management Inc. increased its position in Hologic by 49.5% in the first quarter. Envestnet Asset Management Inc. now owns 39,245 shares of the company’s stock worth $1,354,000 after buying an additional 12,995 shares during the period. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Hologic during the first quarter worth $12,620,000. Institutional investors own 96.42% of the company’s stock.

HOLX has been the topic of several analyst reports. Zacks Investment Research lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, November 7th. Evercore ISI reissued a “buy” rating and issued a $43.00 target price on shares of Hologic in a research note on Saturday, October 15th. Leerink Swann reissued a “buy” rating and issued a $46.00 target price on shares of Hologic in a research note on Thursday, July 28th. Canaccord Genuity set a $45.00 price target on Hologic and gave the stock a “buy” rating in a research report on Thursday, July 28th. Finally, Jefferies Group raised their price target on Hologic from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, July 28th. Six equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $43.20.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.